Cantor Fitzgerald Weighs in on Lumos Pharma, Inc.’s FY2023 Earnings (NASDAQ:LUMO)

Lumos Pharma, Inc. (NASDAQ:LUMOGet Rating) – Cantor Fitzgerald issued their FY2023 EPS estimates for shares of Lumos Pharma in a report issued on Monday, June 6th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of ($4.25) for the year.

NASDAQ LUMO opened at $7.94 on Wednesday. The stock has a 50-day moving average of $8.32 and a two-hundred day moving average of $8.38. Lumos Pharma has a 1-year low of $6.15 and a 1-year high of $12.05.

Lumos Pharma (NASDAQ:LUMOGet Rating) last issued its quarterly earnings data on Thursday, March 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.24. The business had revenue of $0.22 million for the quarter.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in shares of Lumos Pharma by 22.3% in the 3rd quarter. Geode Capital Management LLC now owns 28,356 shares of the company’s stock valued at $269,000 after buying an additional 5,164 shares during the period. PVG Asset Management Corp purchased a new stake in Lumos Pharma in the fourth quarter valued at approximately $71,000. Envestnet Asset Management Inc. purchased a new stake in Lumos Pharma in the fourth quarter valued at approximately $72,000. Citadel Advisors LLC purchased a new stake in Lumos Pharma in the third quarter valued at approximately $113,000. Finally, Millennium Management LLC purchased a new stake in Lumos Pharma in the third quarter valued at approximately $146,000. Institutional investors and hedge funds own 38.35% of the company’s stock.

About Lumos Pharma (Get Rating)

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.

Featured Stories

Earnings History and Estimates for Lumos Pharma (NASDAQ:LUMO)

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.